When will Evolus report its third quarter 2024 financial results?

Evolus is set to release its third quarter 2024 financial results on November 6, 2024, after the markets close.

What will happen after Evolus reports its financial results?

A conference call will follow the results, starting at 4:30 p.m. ET on the same day, which will include a question-and-answer session.

How can investors participate in the conference call for Evolus' financial results?

Participants can join the conference call by dialing (877) 407-6184 for the U.S. or (201) 389-0877 for international calls, or they can connect via a live webcast on the Evolus Investor Relations page.

What new products is Evolus planning to launch and when?

Evolus plans to launch its new injectable hyaluronic acid products, under a definitive agreement to be the exclusive U.S. and European distributor, pending regulatory approval which is expected by 2025.

What is Evolus' strategy for expanding its product offerings?

Evolus is expanding its product portfolio with plans centered on its flagship product Jeuveau® and additional products derived from its exclusive distribution agreements.

Evolus to Report Third Quarter Financial Results on November 6, 2024

10/23/24 8:00:00 AM ET

$EOLS

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $EOLS alert in real time by email

Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its third quarter 2024 financial results on Wednesday, November 6, 2024, after the U.S. financial markets close.

Evolus management will host a conference call and live webcast to discuss these results at 4:30 p.m. ET that same day. A question-and-answer session will follow management's remarks.

To participate in the conference call, dial (877) 407-6184 (U.S.) or (201) 389-0877 (international) or connect live via webcast on the Investor Relations page of the Evolus website here.

Following the completion of the call, a telephonic replay can be accessed by dialing (877) 660-6853 (U.S.) or (201) 612-7415 (international) and using conference number 13749542. An archived webcast can also be accessed on the Investor Relations page of the Evolus website at www.evolus.com.

About Evolus, Inc.

Evolus (NASDAQ:EOLS) is a global performance beauty company evolving the aesthetic neurotoxin market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. Our mission is to become a global, multi-product aesthetics company based on our flagship product, Jeuveau^® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure™ technology. Evolus is expanding its product portfolio having entered into a definitive agreement to be the exclusive U.S. distributor of Evolysse™, and the exclusive distributor in Europe of Estyme^®, a line of unique hyaluronic acid (HA) products. These injectable HA products are currently in the late stages of the regulatory approval process, with plans, upon approval, for a launch starting in 2025. Visit us at www.evolus.com, and follow us on LinkedIn, X, Instagram or Facebook.

Jeuveau^® and Nuceiva^® are registered trademarks and Evolysse^™ is a trademark of Evolus, Inc.

Hi-Pure^™ is a trademark of Daewoong Pharmaceutical Co, Ltd.

Estyme^® is a trademark of Symatese Aesthetics S.A.S.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241023091239/en/

Get the next $EOLS alert in real time by email

Date	Price Target	Rating	Analyst
1/29/2024	$10.00 → $16.00	Equal Weight → Overweight	Barclays
6/23/2022	$18.00	Buy	Needham
5/12/2022	$8.00 → $10.00	Underweight → Equal Weight	Barclays
1/20/2022	$11.00	Hold → Buy	Truist
11/3/2021	$22.00 → $15.00	Buy	HC Wainwright & Co.

Date

Price Target

Rating

Analyst

1/29/2024

$10.00 → $16.00

Equal Weight → Overweight

Barclays

6/23/2022

$18.00

Buy

Needham

5/12/2022

$8.00 → $10.00

Underweight → Equal Weight

Barclays

1/20/2022

$11.00

Hold → Buy

Truist

11/3/2021

$22.00 → $15.00

Buy

HC Wainwright & Co.

Evolus to Report Third Quarter Financial Results on November 6, 2024

Chat with this insight

Q&A

When will Evolus report its third quarter 2024 financial results?

What will happen after Evolus reports its financial results?

How can investors participate in the conference call for Evolus' financial results?

What new products is Evolus planning to launch and when?

What is Evolus' strategy for expanding its product offerings?

Recent Analyst Ratings for $EOLS

$EOLS SEC Filings

SEC Form 10-Q filed by Evolus Inc.

Evolus Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

Evolus Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

$EOLS Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G filed by Evolus Inc.

SEC Form SC 13G/A filed by Evolus Inc. (Amendment)

SEC Form SC 13G/A filed by Evolus Inc. (Amendment)

$EOLS Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Financial Officer Beaver Sandra sold $49,074 worth of shares (3,276 units at $14.98), decreasing direct ownership by 2% to 148,502 units (SEC Form 4)

Chief Marketing Officer Yamagishi-Dressler Tomoko sold $89,251 worth of shares (5,631 units at $15.85), decreasing direct ownership by 6% to 82,375 units (SEC Form 4)

Director White Albert G Iii was granted 23,014 shares (SEC Form 4)

$EOLS Leadership Updates

Live Leadership Updates

$EOLS Market Insights

Live Market Insights

Evolus Announces Appointment of Albert G. White III to Board of Directors

Evolus Announces the Appointment of Nareg Sagherian to Vice President, Head of Global Investor Relations and Corporate Communications

Evolus Appoints Tomoko Yamagishi-Dressler as Chief Marketing Officer

Evolus Announces Submission Of Premarket Approval Application To The U.S. FDA For First Two Evolysse Dermal Filler Products

Cantor Fitzgerald Reiterates Overweight on Evolus

Evolus Expands International Presence With Launch Of Nuceiva In Spain

$EOLS Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Evolus upgraded by Barclays with a new price target

Needham initiated coverage on Evolus with a new price target

Evolus upgraded by Barclays with a new price target

$EOLS Press Releases

Fastest customizable press release news feed in the world

Evolus to Participate in Stifel 2024 Healthcare Conference

Evolus Announces EU Approval of Estyme® Injectable Hyaluronic Acid Gels Under New Medical Device Regulation

Evolus Rewards™ Patient Loyalty Program Surpasses 1 Million Enrolled Consumers

$EOLS Financials

Live finance-specific insights

Evolus to Report Third Quarter Financial Results on November 6, 2024

Evolus to Report Second Quarter Financial Results on July 31, 2024

Evolus Reports First Quarter 2024 Results and Provides Business Update

Recent Analyst Ratings for
$EOLS

$EOLS
SEC Filings

$EOLS
Large Ownership Changes

$EOLS
Insider Trading

$EOLS
Leadership Updates

$EOLS
Market Insights

$EOLS
Analyst Ratings

$EOLS
Press Releases

$EOLS
Financials